Drug Profile
Alternaria alternata immunotherapy
Alternative Names: A. alternata immunotherapyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bial
- Developer BIAL
- Class Allergens; Antiallergics; Fungal allergy immunotherapies; Mould allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Allergic rhinitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-asthma in Spain (SC)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis in Spain (SC)
- 10 Mar 2008 Clinical trials in Allergic asthma in Spain (SC)